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Submucosal fibroids account for 10% of total fibroids. They significantly impact 
quality of life causing abnormal uterine bleeding (AUB), reduction in fertility 
rates/infertility, obstetrics complications and abdominal pain. They are a major 
public health concern because of economic cost their monitoring and treatment 
requires. Hysteroscopic myomectomy is the first line minimally invasive and 
conservative surgical treatment. Treating a fibroid correctly implies knowing its 
physiopathology: What is a submucosal fibroids and what is its origin, what is 
the Pseudocapsule?. Proper diagnosis and standardized classification such as the 
Wamsteker classification are required. What are the limits to perform a hystero-
scopic myomectomy? What devices are currently used? What are the requirements 
for conducting myomectomy procedures in the outpatient setting?. Different forms 
of surgical approach. Complications and consequences of a myomectomy. What 
will we do in the future with the management of small submucosal fibroids in 
asymptomatic patients with future genetic desires and can we resect type 3 fibroids 
by hysteroscopy avoiding a higher risk surgery by abdominal route?
Keywords: submucosal fibroid, pseudocapsule, hysteroscopic approach,  
outpatient myomectomy, economic impact
1. Introduction
Uterine fibroids are the most common benign pelvic tumors of the female geni-
tal tract. Their incidence is approximately 25–30% and may be higher depending on 
race, family history and genetics. Although most fibroid tumors are asymptomatic, 
they are a significant health issue due to the economic cost incurred by healthcare 
systems to monitor and treat them. The impact on the quality of life of women with 
this condition can be considerable.
Direct medical care expenses include surgery, treatment expenses for outpatient 
care and monitoring expenses. The indirect expenses include costs derived from 
inability to work and deterioration in the ability to perform usual tasks. Moreover, 
they include the expenses for obstetrical complications related to their presence or 
treatment. Obstetrical morbidity costs amount to $7.76 billion in the annual costs of 
myoma in the US. They cost more each year in the US than breast, ovarian and colon 
cancer [1–3].
When talking about fibroids and hysteroscopy, we are talking about submucosal 
fibroids, since they are the types of fibroids in the FIGO classification that can be 
approached in this way (FIGO Leiomyoma classification system) (Figure 1).
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Submucosal fibroids amount to 5.5–10% of all uterine fibroids. They are fre-
quently associated with abnormal uterine bleeding and infertility: women with 
submucous myomas are less likely to conceive, have significantly higher miscar-
riage rates and lower rates of successful deliveries, regardless of the conceptive 
method. There is scientific proof to support this fact. They have an impact on the 
functioning of the uterus and they cause changes in the normal anatomy of the 
uterus, alterations in blood supply, increased contractility, local hormonal changes 
and an action on the genetic expression of the endometrium (the endometrial RNA 
levels of HOXA11, LIF and BTEB1 decrease significantly in unfertile patients with 
uterine fibromas compared to healthy fertile control subjects at the moment of 
implantation). Removal of the myoma increases the fertility potential and the IVF 
results, increasing pregnancy rates from 17% to up to 80% according to the series. 
Therefore, it is reasonable to recommend surgical treatment in women who want to 
get pregnant and women that present abnormal uterine bleeding (AUB) [4–6].
Hysteroscopic myomectomy can be considered as the first-line minimally-inva-
sive surgical treatment for submucosal myomas. This technique allows submucosal 
fibroids to be removed and the uterus to be preserved with minimal complications 
and rapid recovery times [7–10].
The execution of surgical hysteroscopy on an outpatient setting has turned into 
the gold standard of the medical practice.
There are many benefits to performing hysteroscopy in an outpatient setting, 
provided it is done safely and effectively, compared to hysteroscopy in the operat-
ing room: it does not require hospital admission, preoperative testing, or general 
or local anesthesia; it decreases post-surgical recovery times and overall procedure 
costs and it improves procedure satisfaction level for both healthcare providers and 
patients [11–15].
2. Submucosal myoma. Physiopathology
Submucosal fibroids are those fibroids that grow into the uterine cavity 
(Figure 2).
2.1 Origin submucosal fibroid
In order to treat a fibroid correctly, we must know its origin and the concept of 
pseudocapsule.
Figure 1. 
FIGO Leiomyomas subclassification system.
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Fibroids are benign tumors that develop from a myometrial cell. It is not 
known why a myometrial cell starts multiplying uncontrollably, but we do know 
that their growth is estrogen-dependent. Fibroids have the mechanical capacity to 
push the healthy myometrium around them; the mechanical properties of fibroids 
are a key factor in their growth. Due to the compression exerted on surrounding 
structures, the fibroid induces gradual formation of a protective structure known 
as pseudocapsule that separates the fibroids from healthy uterine tissue. They 
grow inside the myometrium towards the least-resistance zone and, in the case of 
submucous myomas, they grow into the endometrial cavity. Submucosal myomas 
G0, G1 and G2 are classified as different transition phases of the same myoma 
[16] (Figure 3).
2.2 Pseudocapsule
Pseudocapsules are entities whose existence has been proven both histologically 
and through Doppler echography (this structure is seen as a ring of fire on an echo-
gram). It has a different genetic expression profile than a normal myometrium and 
the surrounding myoma. This pseudocapsule is an independent entity, expressed 




Transition phases of fibroids.
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blood vessels and neurofibers and it is rich in neuropeptides and neurotransmit-
ters. These substances are believed to have an important role in wound healing and 
nerve repair, and they may be important for sexual and reproductive functions after 
resection of the myoma.
The fibroid is anchored through the pseudocapsule through connective bridges 
and small vessels creating a clear abscission plane between the fibroid and the 
pseudocapsule.
Contrary to popular belief, and except for pedunculated fibroids, other fibroids 
do not have a vascular pedicle that feeds them. The neurovascular network of the 
pseudocapsule is responsible for their irrigation (Figure 4) [17, 18].
3. Hysteroscopy: diagnosis and treatment
Hysteroscopy is currently the gold standard used to diagnose and determine the 
feasibility of resection of submucosal fibroids. It allows direct visualization of the 
uterine cavity and the identification of other intracavitary lesions. However, it only 
provides a subjective assessment of the size of the fibroid and indirect information 
about the degree of extension of the fibroid into the endometrial cavity.
3.1 Historical perspective
During the last two decades, thanks to advances in instruments and refine-
ment of techniques, hysteroscopic myomectomy has acquired the status of ‘surgi-
cal technique’ and, today, represents the minimally invasive standard surgical 
procedure for the treatment of fibroids totally or mostly located in the uterine 
cavity.
William Norment performed the first hysteroscopic myomectomy in 1957 using 
the cutting handle. In 1976, Neuwirth and Amin reported a transcervical approach 
to excision of fibroids using a combination of techniques such as electrocautery 
and egg forceps. Neuwirth subsequently introduced a new technique for the 
resection of submucosal fibroids using the urologic resectoscope in 1978. Glycine 
(1.5% solution) was used for the first time by Haning et al. as a means of disten-
tion. Hallez created a specially designed dual-flow resectoscope for the uterus that 
allows full myomectomies even in cases of embedded fibroids. The gynecological 
resectoscope is currently the instrument of choice for the treatment of submucosal 
fibroids but mechanical morcellators are gaining popularity due to their mechanical 
Figure 4. 
Pseudocapsule and abscission plane.
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characteristics for the performance of myomectomy and their lower rates of com-
plications and synechiae after myoma surgery [19–23].
3.2 Other diagnostic procedures
There are other less invasive diagnostic procedures such as sonohysterography 
(SHG) that can provide better objective knowledge of the fibroid and with less cost 
and low complication rate.
Two-dimensional ultrasound with installation of sterile physiological saline in 
the endometrial cavity called sonohysterography is an established technique that 
allows the visualization of intracavitary lesions such as submucosal myomas with 
a higher precision than conventional two-dimensional ultrasound and comparable 
to that of diagnosis hysteroscopy. In addition, SHG allows an accurate assessment 
of the number of fibroids, measurement of fibroid size, and the thickness of the 
overlying myometrium, which is called the myometrial free margin.
The myometrial free margin is a limiting factor for safe myoma resection during 
hysteroscopic myomectomy, but we can fix this problem by taking advantage of 
the contractile capacity of the myometrium with different pressure changes of the 
distension medium [24].
3.3 Classification: fibroid types 0, 1, and 2
In 1993, in the face of the surgical complexity posed by some deeply penetrating 
submucosal myomas, Wamsteker et al. proposed a classification system for submu-
cosal fibroids to predict the difficulty of the surgical procedure, depending on the 
penetration degree of the fibroid in the myometrium. With this classification, gyne-
cologists can estimate the likelihood of completing the hysteroscopic removal of the 
submucosal fibroid in a single procedure. The Wamsteker classification was adopted 
by the European Gynecological Endoscopy Society (ESGE) and the leiomyoma 
classification system of the International Federation of Gynecology and Obstetrics 
(FIGO) includes the Wamsteker classification for submucosal fibroids, depending 
on the penetration degree of the fibroid in the myometrium, the fibroid will form 
an angle with the uterine cavity: Type 0 = fibroids attached to the cavity by a narrow 
pedicle, Type 1 = fibroids with an angle of less than 90° with the adjacent uterine 
wall, Type 2 = fibroids forming an angle of 90° or more with the adjacent uterine 
wall (Figure 5).
Figure 5. 




Should we treat all submucosal fibroids in the same way?
The approach to G0 fibroids with pedicles and without an intramural component 
should be different from G1-G2 fibroids that have an intramural component. We 
need to standardize the therapeutic approach to fibroids and follow pre-established 
guidelines [19, 25, 26].
4.1 Approach to fibroid type 0
It is recommended to cut the vascular pedicle and then the extract the fibroid 
with forceps, morcellation, vaporization, etc. These options depend on the size of 
the fibroid. Some authors recommend leaving the fibroma fragments inside the 
uterine cavity, which will be expelled naturally after several menstrual cycles.. 
There are other authors who advise against it due to bleeding and colicky pain until 
expulsion. A preliminary biopsy will always be necessary, if left ̈ in situ ̈ until its 
expulsion.
4.2 Approach to fibroid types 1 and 2
The general principle for a correct myomectomy is the enucleation of the 
fibroid; for that purpose, we must find the correct plane and that is the pseudo-
capsule plane. Enucleation of the fibroid through the pseudocapsule allows for 
preservation of the neurovascular network of the myoma, rich in neuropeptides 
and neurotransmitters, which are important for a correct healing of the affected 
myometrium. When cutting at the correct plane of the pseudocapsule, we find lax 
bridges of connecting tissue and multiple capillaries or small vessels. Dissecting 
this plane is easy due to its laxity, and it progressively detaches from the fibroid 
while its irrigation becomes compromised by cutting off the surrounding irrigation. 
Dissection of the correct layer decreases bleeding during surgery.. Another benefit 
of retaining its plane is the preservation of the integrity of the underlying myo-
metrium, thus preventing scars. Scars on the myometrium affect fertility after the 
procedure and contribute to the formation of post-surgical adhesions.
There are different techniques to approach the pseudocapsule, but in all of them 
we have to weaken the endometrial surface that covers the fibroid and that contains 
it within the intramural plane, we must weaken it to allow the fibroid to protrude 
into the uterine cavity, helped by the pressure changes of the median distensor 
and physiological myometrial contraction. The technique to address fibroids will 
depend on the intracavitary component:
On the one hand, if the fibroid has a small intracavitary component, we can 
choose one of the following techniques: all of them involve making an incision in 
the endometrial lining of the fibroid and promote the protrusion of the fibroid 
inside the uterine cavity. We can remove the fibroid in one or two step.
Bettochi technique (OPPIuM). this incision is made on the line of the reflection 
of the fibroid with uterine wall.
Myomectomy in toto. In this technique the incision is elliptical.
On the other hand, if the fibroid has a large intracavitary component, first we 
resect this component, then to perform the enucleation of the pseudocapsule and 
lastly remove the rest of fibroid, using the following techniques:
Mazzon technique. Also known as the “Cold loop” technique, developed by 
Mazzon in 1995, it uses monopolar or bipolar electrodes by slicing the intracavitary 
component and the Cold loop. It is a mechanical instrument to perform the enucle-
ation of the pseudocapsule.
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This technique is characterized by a sequence of three different opera-
tional steps:
First, the intracavitary portion of the fibroid is cut by repeated and progressive 
steps of a semicircular monopolar cut. This action stops at the plane of the endome-
trial surface so that the passage between the fibroid and the adjacent myometrium 
are clearly identified (pseudocapsule). Second, cold enucleation of the intramural 
portion of the fibroid is performed by pulling and lever maneuvers with non-elec-
trical “cold” loops. Once the intracavitary portion is resected, the usual cutting loop 
is replaced on the same resectoscope using a suitable cold loop blunt dissection. By 
gentle traction on the fibroid, the pseudocapsule is clearly identified and the cold 
loops are then inserted into this avascular space. These loops are progressively used 
in a mechanical form that hooks and lacerates the connective bridges that join the 
fibroid to normal tissue.
Lastly, the removal of the enucleated intramural portion is completed by 
progressive cutting, being completely dislocated and therefore safely treatable 
as a lesion with a total intracavitary development which can thus be completely 
and safely excised by standard progressive excision using an angled cutting 
loop [27].
Hydromassage Technique. It changes the distention pressures of the uterine 
cavity, which achieves the same effect as the mechanical instruments such as Cold 
loop and Tissue Removal device (TRD).
Hydromorcellation Technique: Maneuvers combined with the TRD and the 
irrigation system (continuous infusion pump) are performed to distend the intra-
uterine cavity, making changes in intrauterine pressure with rises and falls of flows 
that will favor myometrial contractions.
The objective of this combined technique is to weaken the endometrial surface 
that lines the fibroid and thus allow the fibroid to protrude into the cavity. To 
weaken the endometrial surface that covers the fibroid, we will use the TRD and to 
promote the protrusion of the fibroid into the uterine cavity with the contractions 
of the myometrium, we will perform “hydromassage maneuvers” with changes in 
the flow of intrauterine distension.
We will approach the TRD to the surface that covers the fibroma, either in 
its upper pole or in the cleavage plane of the fibroid with the uterine cavity and 
once this surface has been weakened, we will perform maneuvers to change the 
intrauterine distension, lowering and raising the pressures of flow, even stop-
ping the procedure for 1 or 2 minutes, in cases of fibroids with a large intramural 
component.
With these innovative maneuvers to change intrauterine pressure, we promote 
contractions of the myometrium and allow the myoma to protrude into the cavity, 
visualizing the plane of the pseudocapsule and its bridges and proceeding to mor-
cellate the intracavitary portion that protrudes from the intramural portion of the 
myoma [28].
4.3 On-site hysteroscopy
There are many centers where hysteroscopy, even diagnostic hysteroscopy, is 
commonly performed with general anesthesia in the operating room. In reality, 
while it is a challenge to perform hysteroscopy in an outpatient setting, it is even 
harder to convince gynecologists around the world, who are still performing this 
procedure as a surgical procedure that women deserve the option of a less invasive 
approach. While the skillset needed for outpatient hysteroscopy can be demanding, 
global progress in this procedure is patchy. Recommendations for the execution of 
an outpatient hysteroscopy [29–31].
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1. The incorporation of “outpatient hysteroscopy” into clinical practice has 
shown economic benefits (Grade II evidence, Grade A recommendation).
2. Gynecologists should be able to perform outpatient hysteroscopy for the diag-
nosis and treatment of women with abnormal uterine bleeding, infertility and 
intrauterine abnormalities.
3. Outpatient hysteroscopy should be performed in a room of adequate size and 
fully equipped, there must always be an assistant/companion in the room for 
patient safety and privacy (Grade II evidence, Grade B recommendation).
4. The hysteroscopist must have the skills and experience to perform a hysteros-
copy (Grade VI, Grade A recommendation).
5. Written informed consent must be obtained before initiating the procedure.
Moving hysteroscopic procedures outside the operating room and bringing them 
into the outpatient setting facilitates the logistics around hysteroscopy: they are more 
cost-effective, they will improve the productivity of doctors and allow for easier 
surgical scheduling, they will improve patient satisfaction and make recovery times 
shorter. In the United States in 2017, the payment for hysteroscopic polypectomy was 
reduced by $30 when performed in an operating room, while the payment increased 
by $972 when performed as an outpatient procedure. Performing the hysteroscopy as 
a surgical procedure will incur additional costs for anesthesia fees and hospital fees. 
There is a significant benefit in increasing the number of outpatient procedures.
Patients appreciate the convenience of the “see and treat” approach to a gyne-
cological problem and often prefer to avoid the inconvenience of going through 
surgery and the additional risks of undergoing anesthesia. They are associated 
with greater patient satisfaction and faster recovery compared to hysteroscopy in a 
hospital [12, 32].
The treatment sequence will depend on the workflow of each department and 
the surgical material available. It can be done in one step –“see and treat” – or in two 
or more steps, depending on the complexity of the pathology to be treated.
Therefore, it will be possible to conduct a hysteroscopy in an operating room or 
on an outpatient setting.
4.4 Surgical devices
Technological advances in surgical devices over the last 2 decades have brought 
hysteroscopy to maturity in the 21st century, allowing for many outpatient 
procedures.
Reliable equipment is an essential prerequisite for safe surgery.
The advent of modern small diameter (less than 5.5 mm) hysteroscopes, along 
with 5–7 Fr miniature mechanical ancillary instruments (scissors, forceps, bipolar 
electrodes, e.g. Versapoint™ [Gynecare, Ethicon Inc., Menlo Park, CA, USA). U.S]; 
tissue retrieval systems: TRUCLEAR ™ [Smith & Nephew Inc., Andover, MA, UH. 
USA], MyoSure® [Hologic, Marlborough, MA, USA] have led to a paradigm shift 
in surgical interventions leading to procedures that were performed under general 
anesthesia being conducted in an outpatient setting with local anesthesia only and 
if necessary [14, 33].
In 2005, Campo et al. evaluated the effects of instrument diameter, patient 
parity and surgeon experience of pain during office hysteroscopy and the suc-
cess rate of the procedure. They found that all outcomes (pain, visualization and 
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success rate) were largely influenced by patient parity and the diameter of the 
hysteroscope. Compared to less experienced surgeons, those with more experi-
ence caused less procedure pain. In contrast to the use of a hysteroscope with an 
outer diameter of 5 mm, outpatient hysteroscopy with a mini-hysteroscope (outer 
diameter of 3.5 mm) was preferable. The operating hysteroscope contains a work-
ing element which introduces electrosurgical and mechanical instruments for the 
myomectomy surgery [34].
Working with minimal intrauterine distension pressures, sufficient for adequate 
visualization, will reduce patient discomfort and serious complications such as 
fluid overload. Isotonic solutions (normal saline) are recommended as distension 
medium. It is essential that all hysteroscopic surgery offices have a control system 
for the balance fluids during the procedure and a protocol for the management of 
excessive fluid deficit [35–38].
In order to perform outpatient myomectomy, these devices must work quickly 
but the surgeon should also be comfortable with the device that they are using.
It exists new surgical devices with small diameters that can be used for myomas in 
an outpatient setting, without general or local anesthesia and using different types of 
energy such as the Versapoint system with bipolar energy, mechanical TRDs or laser.
4.4.1 Versapoint
Versapoint® with bipolar energy system. Currently, there are 5 bipolar elec-
trodes available on the market, three of these electrodes can be used with small-
diameter hysteroscopes and they have different terminals for specific tasks. The 
three different terminals are: the spring (for vaporization), the twizzle (for cutting) 
and the ball (for coagulation), and the other two electrodes can only be used with a 
classic resectoscope. They cannot be used in an outpatient setting.
4.4.2 Laser
This device achieves different effects depending on the wavelength: cutting, 
coagulation, vaporization. The laser most commonly used in hysteroscopy was the 
Neodymium laser and currently BIOLITEC with Selective Light Vaporization.
4.4.3 Mini-resectoscopy
The Gubbini Mini-resectoscope which has a small diameter for outpatient 
procedures uses terminals with bipolar energy and different tips (ball, loop, blade) 
to perform the same function as traditional resectoscopes.
4.4.4 Hysteroscopic TRDs
The Hysteroscopic TRD is a hysteroscopic mechanical system used to remove 
polyps and submucosal myomas. It has a terminal with a side window and a 
mechanical cutting blade, which rotates and oscillates at the same time. It is based 
on a rotary tubular cutting system with mechanical energy based on suction instead 
of the high-frequency electric power historically used in resectoscopy.
There are two brands in the market for performing outpatient myomectomy 
with different diameters and speeds.
The Truclear 5.0 system was the first mechanical TRD for intrauterine 
pathologies approved by the FDA (Food and Drug Administration) in 2005. It has 
a small diameter of 5 mm, ideal for outpatient procedures without anesthesia, with 
a speed of 750 rpm.
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The MyoSure® system was the second mechanical TRD for intrauterine 
pathologies approved by the FDA in 2009. The MyoSure® suite includes four 
devices (MyoSure MANUAL, LITE, REACH, XL) allowing flexibility to treat 
a wide range of intrauterine pathologies in any setting. MyoSure works at a 
faster speed (8075 rpm), which reduces the duration of the procedure [39, 40]. 
The device can be introduced via the new generation Omni scope (diameter 
from 5.5 mm up to 6 mm) or the MyoSure hysteroscopes (from 6.25 mm up to 
7.25 mm).
5. What factors influence for a successful myomectomy?
The main limiting factor for a successful one-step myomectomy is the 
duration of the procedure because the volume of fluid deficit depends on it, 
which is the main and most serious complication in the process of performing a 
hysteroscopy.
On the one hand, the complexity of myomas (fibroids with intramural penetra-
tion) increases the risk of systemic fluid absorption because the hysteroscopist 
needs more time for the myomectomy and this type of myoma disrupts the integrity 
of the myometrium. On the other hand, the skill level and experience of the hys-
teroscopist influence the duration of the procedure [41].
5.1 Complexity of the fibroid
We must analyze all the characteristics of the myomas before performing the 
myomectomy: size, number, location and type (G0, G1, G2) in order to perform 
a successful myomectomy. Within all existing classifications of submucous 
myoma, the Lasmar classification [42, 43] is the most accurate, even more so if 
associated with the concept of CONTINENT/CONTENT proposed by Haimovich 
(Figures 6 and 7).
The five parameters of STEPW are as follows:
1. Size (S): the largest diameter found by any of the imaging methods. When the 
nodule measures <2 cm, it is given a score of 0; if it is 2.1–5 cm, it gets a score 
of 1; and if it measures >5 cm, it gets a score of 2.
2. Topography (T): defined by the third of the uterine cavity where the fibroid is 
located. If it is in the lower third, the score is 0; if in the middle third, the score 
is 1; and if in the upper third, the score is 2.
3. Extension of the base of the myoma (E): when the fibroid covers one third 
or less of the wall, it is given a score of 0; when the base of the nodule occupies 
between one and two thirds of the wall, the score is 1; and when it affects more 
than two thirds of the wall, the score is 2.
4. Penetration of the nodule into the myometrium (P): when the fibroid is 
completely within the uterine cavity it is given a score of 0; if most of it is in 
the uterine cavity the score is 1; and if most of it is in the myometrium the 
score is 2.
5. Wall (W): when the fibroid is on the lateral wall, 1 extra point is added regard-
less of the third that is affected.
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5.2 Skill level and experience of the hysteroscopist
While the skill set required for outpatient hysteroscopy is still state-of-the-art 
gynecological competence, global progress in this procedure has been irregular. 
Currently, entities such as the Royal College of Obstetrics and Gynecology (RCOG) 
and the International Society of Gynecologic Endoscopy (ISGE) have developed a 
ranking of hysteroscopic procedures, in terms of surgical complexity, guiding the 
accreditation and training in hysteroscopic surgery (Figures 8 and 9) [29, 31].
The resection of fibroids with intramural extension is advisable only for expert 
surgeons as it is technically difficult and has a higher risk of complications than other 
hysteroscopic procedures. Type G1-G2 myomas need a short procedure duration for 
Figure 7. 
The concept continent/content take into consideration the relation between the continent (uterine cavity) and 
content (fibroid).
Figure 8. 
RCOG classification of operative hysteroscopy levels.
Figure 6. 
STEPW submucous fibroid classification.
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complete resection that is only achieved by expert hysteroscopists. Furthermore, the 
difference in equipment does not seem to have a significant impact on surgery for 
safe hysteroscopic myomectomy for fibroids with intramural extension [44].
6. Complications
Hysteroscopic myomectomy is relatively safe, but like any other surgical proce-
dure, it is not without complications. Complication rates of 2% and 2.7% have been 
described in the literature [45, 46].
6.1 Fluid overload. Why is the operating time so important?
The estimated frequency of fluid overload is 0.2%. It is the most serious compli-
cation however not frequent; it is directly related to the duration of the procedure 
and to fibroids with a large surface due to the vascular damage associated to them 
and the subsequent intravasation of liquid due to distension. Therefore, in the exci-
sion of complex fibroids, sometimes it is better to stop and complete the operation 
during a second procedure. Whenever possible, we recommend the use of isotonic 
mediums such as normal saline. The distension mediums must be as low as possible 
while providing adequate distension with an intrauterine pressure of approximately 
70–100 mmHg. This is usually achieved when the medium is suspended for approx-
imately 1–1.5 min above the uterus with the current continuous pressure pumps. 
Garry et al. proved that intravasation of the mediums increases considerably once 
the intrauterine pressure exceeds the mean blood pressure (MBP). Most gynecolo-
gists have a termination threshold of 1000 mL for electrolyte-poor hypotonic 
mediums and 2500 mL for isotonic electrolytes.
6.1.1 How to decrease fluid overload?
There are several options to reduce systemic absorption of fluid such as intracervi-
cal injection of diluted vasopressin solution immediately prior to the procedure, the 
distension pressure in the uterine cavity should not be kept too high, it should be 
Figure 9. 
ISGE classification of operative difficulty.
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maintained below the mean blood pressure (evidence level A, stopping the procedure 
for a few minutes (10′) reduces systemic absorption of fluids by intravascular clotting) 
[35, 38]. There is consistent evidence that preoperative administration of GnRH ago-
nists reduces the risk of systemic fluid absorption and decreases the impact of hypona-
tremic hypotonic encephalopathy, especially in premenopausal women [36, 37].
6.2 Uterine perforations
The frequency is low, 0.13% to 0.76%. The uterus can be pierced with a dila-
tor, hysteroscope, or power source. Management will depend on the size, the site 
of the perforation and whether or not there is a risk of injury to another organ. 
Perforation occurs most frequently at the fundus level without significant bleeding. 
Simple perforation rarely causes further damage and can be managed conserva-
tively with hospitalization, no observation, and appropriate broad-spectrum anti-
biotics. Complex perforation can occur with a mechanical device or energy source 
and therefore can be associated with thermal injury to adjacent structures, includ-
ing the intestine or large vessels. However, the energy sources used in the outpa-
tient setting are usually monopolar or bipolar energy that decrease the propagation 
of energy through the tissue during the process and are therefore safer. Mechanical 
TRDs do not require energy and continuously aspirate resected tissue through the 
device for better visualization and thus reducing the risk of perforation.
6.3 Intrauterine bleeding during procedure
The frequency is about 0.25%. Management will depend on the site, severity, and 
cause of the bleeding. Intrauterine bleeding that occurs during the procedure should 
be immediately obvious and can usually be controlled by spot electrocoagulation. 
If clotting fails to control bleeding, the procedure may need to be terminated and a 
tamponade applied by inserting a Foley catheter and dilating the balloon. The cath-
eter must be left in place for 4–6 hours, after which the bleeding almost always stops.
6.4 Cervical trauma
Outpatient procedures can often be performed without the need to dilate the 
cervix, particularly using the vaginoscopic technique described by Bettocchi et 
al. However, operative hysteroscopy may require cervical dilation. Trauma can be 
treated with pressure, silver nitrate, or sutures. It is best to avoid over dilation of the 
cervix because this can cause the distention medium to leak through the cervix and 
around the hysteroscope.
6.5 Infection
Incidence is between 0.1% and 1.42%. Acute pelvic inflammatory disease after 
hysteroscopic surgery is rare. Diagnosis is made from classic signs and symptoms, 
and treatment should be performed with appropriate antibiotics after vaginal smear 
and blood culture.
7. Other frequent questions regarding the handling of fibroids
7.1 Cervical maturing
There have been studies evaluating the use of cervical “maturing” agents prior 
to hysteroscopy; these are typically prostaglandin analog, misoprostol, progesterone 
Fibroids
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antagonist, mifepristone, or osmotic stents (laminaria stents). The literature 
available does not demonstrate any benefit in the use of ceramic preparations for 
patients undergoing diagnostic hysteroscopy. For patients who undergo surgical 
hysteroscopy and cervical dilation beyond 5 mm in diameter, these agents may be 
especially beneficial in premenopausal women [47, 48].
7.2 Paracervical block
Most outpatient procedures do not require analgesics or anesthesia, but if the 
patient needs any of them, paracervical anesthesia is better. According to the 
Cochrane database publication, anesthesia with paracervical block can decrease 
pain during the procedure and 30 minutes afterwards [49], while the French 
guidelines [50] do not recommend the use of analgesics or anesthesia to conduct 
outpatient hysteroscopy; in England, analgesics are administered by 62.5% of 
physicians [51].
7.3 Antibiotic prophylaxis
There are no studies that show any evidence to indicate antibiotic prophylaxis in 
hysteroscopies.
8. Adhesions
Intrauterine adhesions are frequent, especially after a myomectomy if the plane 
of the pseudocapsule is not respected or when two fibroids are located on opposite 
uterine walls; in this case, it is preferable to perform the myomectomy in multiple 
stages to avoid the formation of adhesions. The use of non-electrical devices (cold 
loop or mechanical TRDs) reduces intrauterine adhesions. Different safe and effec-
tive strategies reduce intrauterine adhesions after hysteroscopic myomectomy: early 
second revision hysteroscopy, barrier methods and, in particular, the barrier of 
non-adhesive gels, insertion of an intrauterine device and 2 months of estrogen and 
progestin therapy (in the form of combined oral contraceptives) [45, 52].
9. Future expectation
9.1  Should we treat small asymptomatic submucosal fibroids in patients who 
want to become?
Small myomas, given that they are benign hormone-dependent tumors, have 
a high growth potential and become symptomatic or cause complications during 
natural or assisted conception and pregnancy. Physicians must always take into 
account the biological effects of hormonal changes and/or high levels of estrogen 
during the reproductive life of a woman.
Even if a submucous myoma is small, it may affect the implantation potential 
of an embryo due to the changes produced in the myometrium, or just by causing 
mechanical compression.
Given that myomas are usually spherical, linear growth in the diameter of a 
myoma corresponds to the squared growth in surface and the cubic growth in 
volume [53].
The Global Congress on Hysteroscopy Scientific Committee [54] recommends 
the following:
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When immediate fertility is not desired and in the presence of 1 asymptomatic 
submucous myoma smaller than 15 mm, hysteroscopic myomectomy is recom-
mended, but expectant management is acceptable. If expectant management is 
favored, clinical surveillance of symptoms and serial transvaginal pelvic ultra-
sounds to monitor growth of the myomas are recommended.
When immediate fertility is a priority and in the presence of 1 asymptomatic 
submucous myomas 15 mm, hysteroscopic myomectomy is recommended.
9.2 Hysteroscopic resection of myoma type 3 (FIGO classification), is it feasible?
Type 3 fibroids are intramural fibroids in contact with the endometrium, but 
lack deformation of the cavity. There is no guideline for this type of fibroids. A 
primary goal of treating fibroid type 3 by hysteroscopic resection is to avoid open or 
laparoscopic myomectomy.. Hysteroscopic resection is a potential alternative to tra-
ditional surgery for this type of fibroids. This procedure should be limited to expert 
surgeons because it is a difficult procedure. These fibroids are not visible within 
the uterine cavity, but can be located by ultrasound at the beginning of surgery and 
resected with one of the techniques described in this chapter. The choice of hys-
teroscopic technique depends mainly on the intramural extension of the myoma, as 
well as personal experience and the available technique. The ultrasound guide is the 
main element to guide a safe resection [55].
10. Conclusions
Submucosal fibroids are a health problem for women and a great economic 
burden for National Health Systems (NHS). Nowadays, hysteroscopic myomectomy 
is the most cost-effective treatment because it can be performed on an outpatient 
setting. This type of minimally invasive surgery requires skill and an experienced 
hysteroscopist and new generation devices.
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